Santhera Sets Out Launch Strategy For CHMP-Backed Duchenne Drug

In a major boost for Santhera and Duchenne muscular dystrophy patients, EU regulators have backed the firm’s Agamree for children aged four years and older and a launch in Germany is scheduled for January.